Lyra Therapeutics Inc (NASDAQ:LYRA) currently has a daily average trading volume of 1.79M but it saw 782821 shares traded in last market. With a market cap of 17.47M USD, the company’s current market price of $0.29 came falling about -4.43 while comparing to the previous closing price of $0.30. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.79 and as low as $0.25. In the recent trading on the day, stock has struck highest price mark of $0.283 while lowest mark touched by it was $0.301.
Taking a look at 20-day trading activity of Lyra Therapeutics Inc (LYRA) gives us an average price of $0.3028, while its current price level is -95.78% below from 52-week high level whereas it is 13.19% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.2946 while that of 200 days or SMA-200 reads an average of $3.1841. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.48% during that period while stretching the period over a month that increases to 8.57%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 38.25 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Jefferies which downgraded the stock as “Hold” in its note to investors issued on May 07, 2024, recommending a price target of between $10 and $0.50 for it. H.C. Wainwright downgraded its recommendation for the stock as a “Neutral” from “Buy” on May 07, 2024 while assigning a price target range of $12-$2.
Over the week, LYRA’s stock price is moving -6.40% down while it is -7.55% when we observe its performance for the past one month. Year-to-date it is -94.53% down and over the past year, the stock is showing a downside performance of -92.15%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.27 beat the consensus estimate of -0.32 for the same. In next quarter, company is expected to be making quarterly sales of $370k as analysts are expecting the sales for current fiscal year at $1.7M and seeing the company making $810k in sales next year. Moreover, analysts are in estimates of $350k for current-quarter revenue.
Currently, Lyra Therapeutics Inc’s total number of outstanding shares is 57.21M with 0.70% of that held by the insiders while 92.78% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -62.13% and return on equity (ROE) at -95.93%. Stock’s beta reads 0.01. Stock has a price to book (P/B) ratio of 0.23 while price to sale or P/S ratio amounts to 10.40. Its return on asset (ROA) is -58.52% on average.
